CALGB 9741 Trial

The CALGB 9741 trial studied women with early-stage breast cancer to determine if adding or changing chemotherapy doses improved treatment outcomes. Patients were randomly assigned to different chemotherapy plans, including standard dosing and more intense regimens with additional drugs or increased dose density (shorter intervals). The goal was to see if these adjustments would improve survival rates and reduce cancer recurrence. The trial found that dose-dense chemotherapy, given more frequently, improved disease-free and overall survival, guiding future treatment strategies to optimize patient outcomes in breast cancer care.